This drug is usually used to treat Type 2 diabetes, but it may result in a greater risk of bladder cancer. Please call our office if you have been diagnosed with bladder cancer after taking this drug. Actos is an oral Type 2 diabetes drug that comes in tablet form. It is not for use in treatment of Type 1 diabetes or diabetic ketoacidosis.
Typically, the dose starts at 15 or 30 mg and is taken once a day. Some people may require a stronger dose, and doctors can increase the strength of the medicine by 15 mg increments. The maximum recommended dose of the drug is 45 mg.
Uses and Concerns
Approved by the U.S. Food and Drug Administration (FDA) in 1999, the Type 2 diabetes drug Actos (pioglitazone) was one of Takeda Pharmaceuticals’ best-selling drugs. With diet and exercise, it helps control blood sugar.
But, it is also a controversial drug that is linked to a number of serious side effects, including congestive heart failure, kidney disease and bladder cancer. But, it is a possible side effect unique to Actos that now raises concern: bladder cancer.
In August 2011, the FDA required that Takeda update the drug’s Warnings and Precautions section of the label to include a warning that use of the drug for over a year may be associated with an increased risk of bladder cancer.
Pioglitazone is marketed as trademarks Actos in the USA, Canada, the UK and Germany, Glustin in Europe, Glizone and Pioz in India by Zydus Cadila and USV Limited, respectively and Zactos in Mexico by Takeda Pharmaceuticals.